Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries

European Journal of Pharmacology

Volumn 557, Issue 1, 2007, Pages 23-31

  Ye, Yi Lu ^a   Shi, Wen Zhen ^a   Zhang, Wei Ping ^a   Wang, Meng Ling ^a   Zhou, Yu ^a   Fang, San Hua ^a   Liu, Li Ying ^a   Zhang, Qi ^a   Yu, Yue Ping ^a   Wei, Er Qing ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Angiogenesis; Astrocyte proliferation; Blood brain barrier; Cerebral ischemia; Cilostazol; Neuroprotection

Indexed keywords

CILOSTAZOL; NEUROPROTECTIVE AGENT; PHOSPHODIESTERASE III INHIBITOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN ATROPHY; BRAIN ISCHEMIA; CONTROLLED STUDY; MALE; MOUSE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; SCAR FORMATION; SINGLE DRUG DOSE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; BRAIN; BRAIN ISCHEMIA; MALE; MICE; MICE, INBRED ICR; NEUROPROTECTIVE AGENTS; PHOSPHODIESTERASE INHIBITORS; TETRAZOLES;

EID: 33846376947     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.11.003     Document Type: Article

References (51)

1. Ahn J.C., Song W.H., Kwon J.A., Park C.G., Seo H.S., Oh D.J., and Rho Y.M. Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel. Korean J. Intern. Med. 19 (2004) 230-236
2. Amano H., Haysahi I., Yoshida S., Yoshimura H., and Majima M. Cyclooxygenase-2 and adenylate cyclase/protein kinase a signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Hum. Cell 15 (2002) 13-24
3. Asai J., Takenaka H., Katoh N., and Kishimoto S. Dibutyryl camp influences endothelial progenitor cell recruitment during wound neovascularization. J. Invest. Dermatol. 126 (2006) 1159-1167
4. Baumgartner I., Pieczek A., Manor O., Blair R., Kearney M., Walsh K., and Isner J.M. Constitutive expression of phvegf165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97 (1998) 1114-1123
5. Bayatti N., and Engele J. Cyclic amp modulates the response of central nervous system glia to fibroblast growth factor-2 by redirecting signalling pathways. J. Neurochem. 78 (2001) 972-980
6. Bederson J.B., Pitts L.H., Tsuji M., Nishimura M.C., Davis R.L., and Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17 (1986) 472-476
7. Beni S.M., Kohen R., Reiter R.J., Tan D.X., and Shohami E. Melatonin-induced neuroprotection after closed head injury is associated with increased brain antioxidants and attenuated late-phase activation of nf-kappab and ap-1. FASEB J. 18 (2004) 149-151
8. Betz A.L., Iannotti F., and Hoff J.T. Brain edema: a classification based on blood-brain barrier integrity. Cerebrovasc. Brain Metab. Rev. 1 (1989) 133-154
9. Bramlett H.M., and Dietrich W.D. Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. J. Cereb. Blood Flow Metab. 24 (2004) 133-150
10. Bush T.G., Puvanachandra N., Horner C.H., Polito A., Ostenfeld T., Svendsen C.N., Mucke L., Johnson M.H., and Sofroniew M.V. Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 23 (1999) 297-308
11. Chen J., Zhang C., Jiang H., Li Y., Zhang L., Robin A., Katakowski M., Lu M., and Chopp M. Atorvastatin induction of vegf and bdnf promotes brain plasticity after stroke in mice. J. Cereb. Blood Flow Metab. 25 (2005) 281-290
12. Choi J.M., Shin H.K., Kim K.Y., Lee J.H., and Hong K.W. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J. Pharmacol. Exp. Ther. 300 (2002) 787-793
13. Dawson D.L., Cutler B.S., Meissner M.H., and Strandness Jr. D.E. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 98 (1998) 678-686
14. del Valle-Perez B., Martinez-Estrada O.M., Vilaro S., Ventura F., and Vinals F. Camp inhibits tgfbeta1-induced in vitro angiogenesis. FEBS Lett. 569 (2004) 105-111
15. Dirnagl U., Simon R.P., and Hallenbeck J.M. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci. 26 (2003) 248-254
16. Gale N.W., and Yancopoulos G.D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: vegfs, angiopoietins, and ephrins in vascular development. Genes Dev. 13 (1999) 1055-1066
17. Hashimoto A., Miyakoda G., Hirose Y., and Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a camp/protein kinase a- and phosphatidylinositol 3-kinase/akt-dependent mechanism. Atherosclerosis 189 (2006) 350-357
18. Hoeben A., Landuyt B., Highley M.S., Wildiers H., Van Oosterom A.T., and De Bruijn E.A. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev. 56 (2004) 549-580
19. Honda F., Imai H., Ishikawa M., Kubota C., Shimizu T., Fukunaga M., and Saito N. Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia. Stroke 37 (2006) 223-228
20. Jacoby D., and Mohler III E.R. Drug treatment of intermittent claudication. Drugs 64 (2004) 1657-1670
21. Kim K.Y., Shin H.K., Lee J.H., Kim C.D., Lee W.S., Rhim B.Y., Shin Y.W., and Hong K.W. Cilostazol enhances casein kinase 2 phosphorylation and suppresses tumor necrosis factor-alpha-induced increased phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and apoptotic cell death in sk-n-sh cells. J. Pharmacol. Exp. Ther. 308 (2004) 97-104
22. Kimura Y., Tani T., Kanbe T., and Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35 (1985) 1144-1149
23. Krupinski J., Kaluza J., Kumar P., Kumar S., and Wang J.M. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 25 (1994) 1794-1798
24. Kurino M., Fukunaga K., Ushio Y., and Miyamoto E. Cyclic amp inhibits activation of mitogen-activated protein kinase and cell proliferation in response to growth factors in cultured rat cortical astrocytes. J. Neurochem. 67 (1996) 2246-2255
25. Kwon S.U., Cho Y.J., Koo J.S., Bae H.J., Lee Y.S., Hong K.S., Lee J.H., and Kim J.S. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 36 (2005) 782-786
26. Lee J.H., Lee Y.K., Ishikawa M., Koga K., Fukunaga M., Miyakoda G., Mori T., Hosokawa T., and Hong K.W. Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats-an mri study. Brain Res. 994 (2003) 91-98
27. Lee J.H., Kim K.Y., Lee Y.K., Park S.Y., Kim C.D., Lee W.S., Rhim B.Y., and Hong K.W. Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats. J. Pharmacol. Exp. Ther. 308 (2004) 896-903
28. Lee J.H., Oh G.T., Park S.Y., Choi J.H., Park J.G., Kim C.D., Lee W.S., Rhim B.Y., Shin Y.W., and Hong K.W. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J. Pharmacol. Exp. Ther. 313 (2005) 502-509
29. Lee J.H., Park S.Y., Shin Y.W., Hong K.W., Kim C.D., Sung S.M., Kim K.Y., and Lee W.S. Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion. Brain Res. 1082 (2006) 182-191
30. Lin T.N., He Y.Y., Wu G., Khan M., and Hsu C.Y. Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke 24 (1993) 117-121
31. Logan A., and Berry M. Cellular and molecular determinants of glial scar formation. Adv. Exp. Med. Biol. 513 (2002) 115-158
32. Lugnier C. Cyclic nucleotide phosphodiesterase (pde) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther. 109 (2006) 366-398
33. Mao Y., Yang G.Y., Zhou L.F., Stern J.D., and Betz A.L. Focal cerebral ischemia in the mouse: description of a model and effects of permanent and temporary occlusion. Brain Res. Mol. Brain Res. 63 (1999) 366-370
34. Netherton S.J., and Maurice D.H. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Mol. Pharmacol. 67 (2005) 263-272
35. Omi H., Okayama N., Shimizu M., Fukutomi T., Nakamura A., Imaeda K., Okouchi M., and Itoh M. Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via no production. Microvasc. Res. 68 (2004) 119-125
36. Park S.Y., Lee J.H., Kim C.D., Lee W.S., Park W.S., Han J., Kwak Y.G., Kim K.Y., and Hong K.W. Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of camp-dependent protein kinase-mediated maxi-k channel activation. J. Pharmacol. Exp. Ther. 317 (2006) 1238-1245
37. Pesic M., Drabek K., Esler C., Ruzdijic S., Pejanovic V., and Pietrzkowski Z. Inhibition of cell growth and proliferation in human glioma cells and normal human astrocytes induced by 8-cl-camp and tiazofurin. Nucleosides Nucleotides Nucleic Acids 19 (2000) 963-975
38. Polverini P.J. Angiogenesis in health and disease: insights into basic mechanisms and therapeutic opportunities. J. Dent. Educ. 66 (2002) 962-975
39. Robinson P.J. Measurement of blood-brain barrier permeability. Clin. Exp. Pharmacol. Physiol. 17 (1990) 829-840
40. Schmued L.C., Albertson C., and Slikker Jr. W. Fluoro-jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 751 (1997) 37-46
41. Shinoda-Tagawa T., Yamasaki Y., Yoshida S., Kajimoto Y., Tsujino T., Hakui N., Matsumoto M., and Hori M. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in japanese subjects with type ii diabetes. Diabetologia 45 (2002) 188-194
42. Silver J., and Miller J.H. Regeneration beyond the glial scar. Nat. Rev. Neurosci. 5 (2004) 146-156
43. Unterberg A.W., Stover J., Kress B., and Kiening K.L. Edema and brain trauma. Neuroscience 129 (2004) 1021-1029
44. Wei L., Erinjeri J.P., Rovainen C.M., and Woolsey T.A. Collateral growth and angiogenesis around cortical stroke. Stroke 32 (2001) 2179-2184
45. Yonemori F., Yamaguchi T., Yamada H., and Tamura A. Evaluation of a motor deficit after chronic focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 18 (1998) 1099-1106
46. Yrjanheikki J., Tikka T., Keinanen R., Goldsteins G., Chan P.H., and Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13496-13500
47. Yu G.L., Wei E.Q., Wang M.L., Zhang W.P., Zhang S.H., Weng J.Q., Chu L.S., Fang S.H., Zhou Y., Chen Z., Zhang Q., and Zhang L.H. Pranlukast, a cysteinyl leukotriene receptor-1 antagonist, protects against chronic ischemic brain injury and inhibits the glial scar formation in mice. Brain Res. 1053 (2005) 116-125
48. Yu G.L., Wei E.Q., Zhang S.H., Xu H.M., Chu L.S., Zhang W.P., Zhang Q., Chen Z., Mei R.H., and Zhao M.H. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. Pharmacology 73 (2005) 31-40
49. Zhang L.H., and Wei E.Q. Neuroprotective effect of ono-1078, a leukotriene receptor antagonist, on transient global cerebral ischemia in rats. Acta Pharmacol. Sin. 24 (2003) 1241-1247
50. Zhang L., Schallert T., Zhang Z.G., Jiang Q., Arniego P., Li Q., Lu M., and Chopp M. A test for detecting long-term sensorimotor dysfunction in the mouse after focal cerebral ischemia. J. Neurosci. Methods 117 (2002) 207-214
51. Zhang W.P., Wei E.Q., Mei R.H., Zhu C.Y., and Zhao M.H. Neuroprotective effect of ono-1078, a leukotriene receptor antagonist, on focal cerebral ischemia in rats. Acta Pharmacol. Sin. 23 (2002) 871-877